BioMarin Pharmaceutical Inc.www.biomarin.com415.506.6700IR@bmrn.com

(Information as of 4Q16)

Corporate OverviewBioMarin is a global biotechnology company that develops and commercializes innovative therapiesfor people with serious and life-threatening rare disorders. The company's portfolio consists of fivecommercialized products and multiple clinical and pre-clinical product candidates.

General Company Information- Founded in 1997- IPO in 1999, NASDAQ ticker BMRN- More that 2,200 employees worldwide- Global sales in 69 markets worldwide

BioMarin Facilities- Headquarters in San Rafael, California- Manufacturing in Novato, California and

Shanbally, Ireland- Regional offices in Dublin, London, Hong

Kong, and Sao Paulo

BioMarin at a Glance- 1300% Increase in revenues from 2006 to 2016- 10th Most Innovative Company for the past 3

years according to Forbes- 20th year of scientific innovation- 5 FDA and EMA approved products- 5 products currently in late-stage development- 1st ERT therapy into the CNS via ICV delivery- 5 years on average from IND to approval for all

marketed products- 171,987,437 shares outstanding

BioMarin Pharmaceutical Inc. · 105 Digital Drive · Novato, CA 94949

Five Commercial Products

BrineuraTM for CLN2

Pegvaliase for PKU

Vosoritide for Achondroplasia

BMN 270 for Hemophilia A

BMN 250 for MPS IIIB

PRECLINICAL TESTING PHASE 1 PHASE 2 PHASE 3 BLA/NDA/MAA COMMERCIALIZATION

2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017E

$441$501

$549

$751

$890

Financial Outlook

Full Year 2017 Revenue Guidance($ in millions)

Item Provided 2/23/17Total BioMarin Revenues $1,250 to $1,300Vimizim $400 to $430Naglazyme $300 to $330Kuvan $380 to $410

Selected Income Statement Guidance ($ in millions, except percentages)

Item Provided 2/23/17Cost of Sales(% of Total Rev.) 17.5% to 18.5%SG&A Expense $520 to $550R&D Expense $620 to $650Non-GAAP Net Income $30 to $70GAAP Net Loss $(140) to $(180)

Actual and Estimated Revenue 2005-2017

VimizimNaglazymeKuvan Aldurazyme + Other

Executive Management Jean-Jacques Bienaimé – Chairman and Chief Executive OfficerRobert A. Baffi, Ph.D. – Executive Vice President, Technical OperationsHank Fuchs, M.D. – President, Worldwide Research and DevelopmentDan Spiegelman – Executive Vice President and Chief Financial OfficerJeff Ajer – Executive Vice President and Chief Commercial Officer

Randy MeierDavid PyottDennis J. Slamon, M.D., Ph.D.Willard H. Dere, M.D.Kathryn E. Falberg

Jean-Jacques BienaiméMichael GreyElaine J. Heron, Ph.D.V. Bryan Lawlis, Ph.D.Alan J. Lewis, Ph.D.

Board of Directors

BioMarin Global Footprint

HeadquartersRegional OfficeManufacturing

(Information as of 4Q16)

$1,117

$1,250 –$1,300

$26

$297

$122$84

$325$376